The FDA approved three new molecular entities (NMEs) in June 2025, contributing to a year-to-date total of 19 approvals with additional approvals already recorded in July. This steady regulatory flow signals ongoing innovation and pipeline maturation in the pharmaceutical sector throughout 2025.